On December 22, 2021, Quidel Corporation (the Company) entered into a Business Combination Agreement (the BCA) by
and among the Company, Ortho Clinical Diagnostics Holdings plc (Ortho), Coronado Topco, Inc. (Topco), Orca Holdco, Inc. (U.S. Holdco Sub) and Laguna Merger Sub, Inc. (U.S. Merger Sub), each a wholly
owned subsidiary of Topco, and Orca Holdco 2, Inc., a wholly owned subsidiary of U.S. Holdco Sub, which provides for a business combination of the Company and Ortho under Topco, a new holding company (the Combinations). Pursuant to the
BCA, the Combinations are expected to be implemented by way of (i) a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act 2006 (the Ortho Scheme), pursuant to which each issued and outstanding share
of Ortho will be acquired by a nominee of Topco, such that Ortho will become a wholly owned subsidiary of Topco, and (ii) a merger of U.S. Merger Sub with and into the Company immediately following consummation of the Ortho Scheme, with the
Company surviving the merger as a wholly owned subsidiary of Topco.
The completion of the Combinations is conditioned upon, among other
things, the early termination or expiration of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), relating to the consummation of the Combinations. Effective as of
11:59 p.m. EST on February 9, 2022, the waiting period under the HSR Act expired with respect to the Combinations.
The completion of
the Combinations remains subject to other closing conditions, including, among others things, (i) receipt of the required Company stockholder and Ortho shareholder approvals, (ii) receipt of certain approvals and clearances required under
the antitrust, competition and foreign investment laws of certain foreign jurisdictions and (iii) sanction of the Ortho Scheme by the High Court of Justice of England and Wales (the Court) and the delivery of the order of the Court
sanctioning the Ortho Scheme to the Registrar of Companies in England and Wales.
Where You Can Find Additional Information
In connection with the proposed Combinations among the Company, Ortho and Topco, Topco has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the Commission) that contains a joint proxy statement/prospectus and other relevant documents concerning the proposed Combinations. YOU ARE URGED TO READ
THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT DOCUMENTS FILED WITH THE COMMISSION (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, ORTHO AND THE PROPOSED COMBINATIONS. The
joint proxy statement/prospectus will be mailed to the Companys stockholders and Orthos shareholders when available. The joint proxy statement/prospectus and the other documents filed with the Commission may also be obtained free of
charge at the Commissions website, www.sec.gov. In addition, you may obtain free copies of the joint proxy statement/prospectus and the other documents filed by the Company and Ortho with the Commission by requesting them in writing from
Quidel Corporation, 9975 Summers Ridge Road, San Diego, California 92121, Attention: Investor Relations, or by telephone at 858-646-8023, or from Ortho Clinical
Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869, Attention: Investor Relations, or by directing a written request to SVC Ortho-SVC@SARDVERB.com.
The Company and Ortho and their respective directors and executive officers may be deemed under the rules of the Commission to be participants
in the solicitation of proxies. Information about the Companys directors and executive officers and their ownership of the Companys common stock is set forth in the joint proxy statement/prospectus. Information about Orthos
directors and executive